Clinical trials: Phase Contrast MRI
- Condition Phase Contrast MRI
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
The objectives of this trial are: 1. To evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers 2.
- Trial name
- NCT05413668
- Testing
- RVP-001
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Reveal Pharmaceuticals Inc.
Magnetic Resonance Imaging
Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects
Study Objectives Primary: To determine MTD and dose limiting toxicities (DLTs) of IOP magnetic resonance imaging (MRI) contrast agent in healthy subjects. Secondary: 1.
- Trial name
- NCT02744248
- Testing
- IOP Injection, 0.9% normal saline
- Where
- Taiwan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MegaPro Biomedical Co. Ltd.
Magnetic Resonance Imaging
Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects
The objective of the study is to assess the dose dependent changes in MRI signal intensity (SI) in liver after IOP Injection intravenous administration in healthy volunteers.
- Trial name
- NCT03399214
- Testing
- IOP Injection
- Where
- Taiwan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MegaPro Biomedical Co. Ltd.